Genelux Corporation (NASDAQ:GNLX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Genelux Corporation (NASDAQ:GNLX) has earned an average rating of “Moderate Buy” from the five research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $18.8333.

A number of research analysts have recently issued reports on GNLX shares. Wall Street Zen upgraded Genelux from a “sell” rating to a “hold” rating in a research report on Saturday, July 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Genelux in a research report on Saturday. HC Wainwright reiterated a “buy” rating on shares of Genelux in a research report on Wednesday, July 23rd. Lake Street Capital started coverage on Genelux in a research report on Tuesday, October 21st. They set a “buy” rating and a $16.00 target price on the stock. Finally, Loop Capital set a $16.00 target price on Genelux in a research report on Tuesday.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in GNLX. Advisor Resource Council acquired a new position in Genelux in the 1st quarter valued at $34,000. 5T Wealth LLC acquired a new position in Genelux in the 1st quarter valued at $49,000. Woodward Diversified Capital LLC raised its stake in Genelux by 15.2% in the 1st quarter. Woodward Diversified Capital LLC now owns 1,461,113 shares of the company’s stock valued at $3,945,000 after purchasing an additional 192,808 shares during the last quarter. Liberty Wealth Management LLC acquired a new position in Genelux in the 1st quarter valued at $45,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Genelux in the 1st quarter valued at $68,000. 37.33% of the stock is owned by institutional investors and hedge funds.

Genelux Trading Up 1.4%

Genelux stock opened at $7.82 on Tuesday. Genelux has a 12 month low of $1.99 and a 12 month high of $8.26. The stock’s 50 day simple moving average is $4.42 and its two-hundred day simple moving average is $3.43. The firm has a market cap of $295.36 million, a PE ratio of -9.09 and a beta of -0.22.

Genelux (NASDAQ:GNLX) last announced its earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02. On average, equities research analysts forecast that Genelux will post -0.88 EPS for the current year.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.